GlassScriptPhysician profile
Tara Kimbason
NPI 1427324888
$119,403.04
in general payments reported to CMS, 2019-2025
27 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,753 · 2020: $8,406 · 2021: $5,873 · 2022: $4,988 · 2023: $5,425 · 2024: $75K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Travel and Lodging: $22K · Food and Beverage: $7,073 · Honoraria: $5,260 · Consulting Fee: $2,420 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,405.00 |
| Travel and Lodging | $22,112.49 |
| Food and Beverage | $7,072.97 |
| Honoraria | $5,260.00 |
| Consulting Fee | $2,420.00 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $95,409.09 | 2019-2025 | Gocovri, Apokyn, Gocovri |
| Insightec,INC | $8,376.16 | 2020-2025 | Exablate |
| Medtronic, INC. | $3,512.99 | 2022-2025 | Percept PC Brainsense, Intellis Adaptivestim, Synchromedii |
| Boston Scientific Corporation | $2,873.72 | 2019-2025 | Vercise, General - Dbs |
| Abbott Laboratories | $2,871.28 | 2019-2024 | Infinity |
| Amneal Pharmaceuticals LLC | $2,165.64 | 2019-2023 | Rytary |
| Medtronic USA, INC. | $1,514.73 | 2019-2020 | |
| Abbvie INC. | $454.55 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $279.95 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $254.03 | 2021-2024 | Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $241.00 | 2019-2024 | Nuplazid |
| Lundbeck LLC | $218.70 | 2019-2024 | Vyepti |
| Kyowa Kirin, INC. | $134.26 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $132.37 | 2020-2021 | |
| Adamas Pharmaceuticals, INC. | $125.84 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $121.15 | 2020 | |
| Sunovion Pharmaceuticals INC. | $111.65 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $111.60 | 2023 | |
| Neurocrine Biosciences, INC. | $108.43 | 2021-2024 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $105.83 | 2019 | |
| Acorda Therapeutics, INC | $84.55 | 2020-2021 | |
| Ucb, INC. | $51.32 | 2022-2024 | Briviact, Rystiggo |
| Lilly USA, LLC | $43.70 | 2021-2024 | Amyvid |
| Allergan, INC. | $38.76 | 2020-2021 | |
| Pfizer INC. | $23.28 | 2024 | |
| Merz Pharmaceuticals, LLC | $21.04 | 2021 | |
| Biogen, INC. | $17.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Kimbason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.